# Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study

> **NCT02239237** · — · COMPLETED · sponsor: **Zhong Wang** · enrollment: 30283 (actual)

## Conditions studied

- Safety Surveillance
- Adverse Drug Events
- Adverse Drug Reactions
- Severe Adverse Events
- Severe Adverse Reactions

## Interventions

- **DRUG:** Compound Kuh-seng Injection

## Key facts

- **NCT ID:** NCT02239237
- **Lead sponsor:** Zhong Wang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2018-06
- **Final completion:** 2018-10
- **Target enrollment:** 30283 (ACTUAL)
- **Last updated:** 2018-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02239237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02239237, "Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02239237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*